Two-Drug Regimens for HIV—Current Evidence, Research Gaps and Future Challenges

During the last 30 years, antiretroviral treatment (ART) for human immunodeficiency virus (HIV) infection has been continuously evolving. Since 1996, three-drug regimens (3DR) have been standard-of-care for HIV treatment and are based on a protease inhibitor (PI) or a non-nucleoside reverse transcri...

ver descrição completa

Detalhes bibliográficos
Autores: Pérez González, Alexandre, Suárez García, Inés, Ocampo, Antonio, Poveda, Eva
Formato: artículo
Fecha de publicación:2022
País:España
Recursos:Universidad Europea (UEM)
Repositorio:ABACUS. Repositorio de Producción Científica
Idioma:inglés
OAI Identifier:oai:abacus.universidadeuropea.com:11268/12178
Acesso em linha:http://hdl.handle.net/11268/12178
Access Level:acceso abierto
Palavra-chave:Antirretrovirales
Virología
Tratamiento médico
Sida
id ES_02eeeba5de787c824c2b59a852df7162
oai_identifier_str oai:abacus.universidadeuropea.com:11268/12178
network_acronym_str ES
network_name_str España
repository_id_str
spelling Two-Drug Regimens for HIV—Current Evidence, Research Gaps and Future ChallengesPérez González, AlexandreSuárez García, InésOcampo, AntonioPoveda, EvaAntirretroviralesVirologíaTratamiento médicoSidaDuring the last 30 years, antiretroviral treatment (ART) for human immunodeficiency virus (HIV) infection has been continuously evolving. Since 1996, three-drug regimens (3DR) have been standard-of-care for HIV treatment and are based on a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI) plus two nucleoside reverse transcriptase inhibitors (NRTIs). The effectiveness of first-generation 3DRs allowed a dramatic increase in the life expectancy of HIV-infected patients, although it was associated with several side effects and ART-related toxicities. The development of novel two-drug regimens (2DRs) started in the mid-2000s in order to minimize side effects, reduce drug–drug interactions and improve treatment compliance. Several clinical trials compared 2DRs and 3DRs in treatment-naïve and treatment-experienced patients and showed the non-inferiority of 2DRs in terms of efficacy, which led to 2DRs being used as first-line treatment in several clinical scenarios, according to HIV clinical guidelines. In this review, we summarize the current evidence, research gaps and future prospects of 2DRs20232023-07-1820222022-01-0120222022-01-01journal articlehttp://purl.org/coar/resource_type/c_6501info:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/11268/12178reponame:ABACUS. Repositorio de Producción Científicainstname:Universidad Europea (UEM)Inglésengopen accesshttp://purl.org/coar/access_right/c_abf2Attribution 4.0 International (CC BY 4.0)https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:abacus.universidadeuropea.com:11268/121782026-06-11T12:41:27Z
dc.title.none.fl_str_mv Two-Drug Regimens for HIV—Current Evidence, Research Gaps and Future Challenges
title Two-Drug Regimens for HIV—Current Evidence, Research Gaps and Future Challenges
spellingShingle Two-Drug Regimens for HIV—Current Evidence, Research Gaps and Future Challenges
Pérez González, Alexandre
Antirretrovirales
Virología
Tratamiento médico
Sida
title_short Two-Drug Regimens for HIV—Current Evidence, Research Gaps and Future Challenges
title_full Two-Drug Regimens for HIV—Current Evidence, Research Gaps and Future Challenges
title_fullStr Two-Drug Regimens for HIV—Current Evidence, Research Gaps and Future Challenges
title_full_unstemmed Two-Drug Regimens for HIV—Current Evidence, Research Gaps and Future Challenges
title_sort Two-Drug Regimens for HIV—Current Evidence, Research Gaps and Future Challenges
dc.creator.none.fl_str_mv Pérez González, Alexandre
Suárez García, Inés
Ocampo, Antonio
Poveda, Eva
author Pérez González, Alexandre
author_facet Pérez González, Alexandre
Suárez García, Inés
Ocampo, Antonio
Poveda, Eva
author_role author
author2 Suárez García, Inés
Ocampo, Antonio
Poveda, Eva
author2_role author
author
author
dc.contributor.none.fl_str_mv
dc.subject.none.fl_str_mv Antirretrovirales
Virología
Tratamiento médico
Sida
topic Antirretrovirales
Virología
Tratamiento médico
Sida
description During the last 30 years, antiretroviral treatment (ART) for human immunodeficiency virus (HIV) infection has been continuously evolving. Since 1996, three-drug regimens (3DR) have been standard-of-care for HIV treatment and are based on a protease inhibitor (PI) or a non-nucleoside reverse transcriptase inhibitor (NNRTI) plus two nucleoside reverse transcriptase inhibitors (NRTIs). The effectiveness of first-generation 3DRs allowed a dramatic increase in the life expectancy of HIV-infected patients, although it was associated with several side effects and ART-related toxicities. The development of novel two-drug regimens (2DRs) started in the mid-2000s in order to minimize side effects, reduce drug–drug interactions and improve treatment compliance. Several clinical trials compared 2DRs and 3DRs in treatment-naïve and treatment-experienced patients and showed the non-inferiority of 2DRs in terms of efficacy, which led to 2DRs being used as first-line treatment in several clinical scenarios, according to HIV clinical guidelines. In this review, we summarize the current evidence, research gaps and future prospects of 2DRs
publishDate 2022
dc.date.none.fl_str_mv 2022
2022-01-01
2022
2022-01-01
2023
2023-07-18
dc.type.none.fl_str_mv journal article
http://purl.org/coar/resource_type/c_6501
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv http://hdl.handle.net/11268/12178
url http://hdl.handle.net/11268/12178
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International (CC BY 4.0)
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
Attribution 4.0 International (CC BY 4.0)
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:ABACUS. Repositorio de Producción Científica
instname:Universidad Europea (UEM)
instname_str Universidad Europea (UEM)
reponame_str ABACUS. Repositorio de Producción Científica
collection ABACUS. Repositorio de Producción Científica
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869402691282665472
score 15,300724

Registos relacionados